The expression of FHIT, PCNA and EGFR in benign and malignant breast lesions

British Journal of Cancer

Volumn 96, Issue 1, 2007, Pages 110-117

  Terry, G ^a   Ho, L ^a   Londesborough, P ^a   Duggan, C ^a   Hanby, A ^b   Cuzick, J ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

BBD; Ca; CIS; EGFR; FHIT; PCNA

Indexed keywords

BRCA1 PROTEIN; CYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR; FORMALDEHYDE; FRAGILE HISTIDINE TRIAD PROTEIN; INTERLEUKIN 1BETA CONVERTING ENZYME; PARAFFIN;

ANTIGEN EXPRESSION; ARTICLE; BREAST DISEASE; BREAST LESION; CARCINOMA IN SITU; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INVASIVE CARCINOMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION;

ACID ANHYDRIDE HYDROLASES; BREAST DISEASES; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMERASE CHAIN REACTION; PROLIFERATING CELL NUCLEAR ANTIGEN; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA; SENSITIVITY AND SPECIFICITY; STAINING AND LABELING;

EID: 33846220006     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603512     Document Type: Article

References (43)

1. Arun B, Kilic G, Yen C, Foster B, Yardley DA, Gaynor R, Ashfaq R (2005) Loss of FHIT expression in breast cancer is correlated with poor prognostic markers. Can Epid Biomarkers Prev 14: 1681-1685
2. Bhargava R, Gerald WL, Li AR, Pan Q, Lal P, Ladanyi M, Chen B (2005) EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations. Mod Path 18: 1027-1033
3. Boudreau N, Sympson CJ, Werb Z, Bissell MJ (1995) Suppression of ICE and apoptosis in mammary epithelial cells by extracellular matrix. Science 267: 891-893
4. Cavalli LR, Singh B, Issacs C, Dickson RB, Haddad BR (2004) Loss of heterozygosity in normal breast epithelial tissue and benign breast lesions in BRCA1/2 carriers with breast cancer. Cancer Gen Cytogen 149: 38-43
5. Campiglio M, Pekarsky Y, Menard S, Tagliabue E, Pilotti S, Croce CM (1999) FHIT loss of function in human primary breast cancer correlates with advanced stage of the disease. Cancer Res 59: 3866-3869
6. Dumon KR, Ishii H, Vecchione A, Trapasso F, Baldassarre G, Chakrani F, Druck T, Rosato EF, Williams NN, Baffa R, During MJ, Huebner K, Croce CM (2001) Fragile histidine triad expression delays tumor development and induces apoptosis in human pancreatic cancer. Cancer Res 61: 4827-4836
7. Elston CW, Sloane JP, Amendoeira I, Apostolikas N, Bellocq JP, Bianchi S, Boecker W, Bussolati G, Coleman D, Connolly CE, Dervan P, Drijkoningen M, Eusebi V, Faverly D, Holland R, Jacquemier J, Lacerda M, Martinez-Penuela J, de Miguel C, Moss S, Munt C, Peterse JL, Rank F, Reiner A, Sylvan M, Wells CA, Zafrani B, European Commission Working Group on Breast Screening Pathology (2000) Causes of inconsistency in diagnosing and classifying intraductal proliferations of the breast. Eur J Cancer 36: 1769-1772
8. Fabian CJ, Kimler BF, Brady DA, Mayo MS, Chang CHJ, Ferraro JA, Zalles CM, Stanton AL, Masood S, Grizzle WE, Boyd NF, Arneson DW, Johnson KA (2002) A phase II breast cancer chemoprevention trial of oral difluoromethylornithine: breast tissue imaging and serum and urine biomarkers. Clin Cancer Res 8: 3105-3117
9. Gatalica Z, Lele SM, Rampy BA, Norris BA (2000) The expression of Fhit protein is related inversely to disease progression in patients with breast carcinoma. Cancer 88: 1378-1383
10. Ginestier C, Bardou V-J, Popovici C, Charafe-Jauffret E, Bertucci F, Geneix J, Adelaide J, Chaffanet M, Hassoun J, Viens P, Jacquemier J, Birnbaum D (2003) Loss of fhit protein expression is a marker of adverse evolution in good prognosis localized breast cancer. Int J Cancer 107: 854-862
11. Golebiowski F, Szulc A, Szutowicz A, Pawelczyk T (2004) Ubc9-induced inhibition of diadenosine triphosphate hydrolase activity of the putative tumor suppressor protein Fhit. Arch Biochem Biophy 428: 160-164
12. Honrado E, Osorio A, Palacios J, Milne RL, Sanchez L, Diez O, Cazorla A, Syrjakoski K, Huntsman D, Heikkila P, Lerma E, Kallioniemi A, Rivas C, Foulkes WD, Nevanlinna H, Benitez J (2005) Immunohistochemical expression of DNA repair proteins in familial breast cancer differentiate BRCA2-associated tumors. J Clin Oncol 23: 7503-7511
13. Hu BC, Wang HY, Wang X, Lu HR, Huang CF, Powell SN, Huebner K, Wang Y (2005) Fhit and CHK1 have opposing effects on homologous recombination repair. Cancer Res 65: 8613-8616
14. Ishii H, Dumon KR, Vecchione A, Fong LYY, Baffa R, Huebner K, Croce CM (2001) Potential cancer therapy with the fragile histidine triad gene. Review of the preclinical studies. JAMA 286: 2441-2449
15. Jarry A, Vallette G, Cassagnau E, Moreau A, Bou-Hanna C, Lemarre P, Letessier E, Le Neel J-c, Galmiche J-P, Laboisse CL (1999) Interleukin 1 and interleukin 1b converting enzyme (caspase 1) expression in the human colonic epithelial barrier. Caspase 1 downregulation in colon cancer. Gut 45: 246-251
16. Jarvis EM, Kirk JA, Clarke CL (1998) Loss of nuclear BRCA1 expression in breast cancers is associated with a highly proliferative tumor phenotype. Cancer Genet Cytogenet 101: 109-115
17. Jee CD, Lee HS, Bae SI, Yang HK, Lee YM, Rho MS, Kim WH (2005) Loss of caspase-1 gene expression in human gastric carcinomas and cell lines. Int J Oncol 26: 1265-1271
18. Knoop AS, Bentzen SM, Nielsen MM, Rasmussen BB, Rose C (2001) Value of epidermal growth factor receptor, HER2, p53 and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients. J Clin Oncol 19: 3376-3384
19. Lebeau A, Unholzer A, Amann G, Kronawitter M, Bauerfeind I, Sendelhofert A, Iff A, Lohrs U (2003 EGFR, Her-2/neu, cyclin D1, p21 and p53 in correlation to cell proliferation and steroid hormone receptor status in ductal carcinoma in situ of the breast. Br Caner Res Treat 79: 187-198
20. Ma X-J, Salunga R, Tuggle T, Gaudet J, Enright E, McQuary P, Payette T, Pistone M, Stecker K, Zhang BM, Zhou Y-X, Varnholt H, Smith B, Gadd M, Charfield E, Kessler J, Baer TM, Erlander MG, Sgroi DC (2003) Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci USA 100: 5974-5979
21. Mady HH, Melhem MF (2002) FHIT protein expression and its relation to apoptosis, tumor histologic grade and prognosis in colorectal adenocarcinoma: an immunohistochemical and image analysis study. Clin Exp Metast 19: 351-358
22. Maitra A, Wistuba II, Washington C, Virmani AK, Ashfaq R, Milchgrub S, Gazdar AF, Minna JD (2001) High-resolution chromosome 3p allelotyping of breast carcinomas and precursor lesions demonstrates frequent loss of heterozygosity and a discontinuous pattern of allele loss. Am J Path 159: 119-130
23. Maniatis T, Fritsch EF, Sambrook J (1982) Molecular cloning. A Laboratory Manual. pp 202- 203. Cold Spring Harbor Laboratory
24. Nishizaki M, Sasaki J, Fang B, Atkinson EN, Minna JD, Roth JA, Ji L (2004) Synergistic tumor suppression by coexpression of FHIT and p53 coincides with FHIT-mediated MDM2 inactivation and p53 stabilization in human non-small cell lung cancer cells. Cancer Res 64: 5745-5752
25. Page DL (1991) Segregation analysis of breast cancer: histopathologic data. JNCI 83: 648
26. Page DL, Dupont WD (1989) Benign breast diseases and premalignant breast disease. Arch Pathol Lab Med 122: 1048-1050
27. Page DL, Jensen RA, Simpson JF, Dupont WD (2000) Historical and epidemiologic background of human premalignant breast disease. J Mammary Gland Biol Neoplasia 5: 341-349
28. Pekarsky Y, Garrison PN, Palamarchuk A, Zanesi N, Aqeilan RI, Huebner K, Barnes LD, Croce CM (2004) Fhit is a physiological target of the protein kinase Src. Proc Natl Acad Sci USA 101: 3775-3779
29. Pekarsky Y, Zanesi N, Palamarchuk A, Huebner K, Croce CM (2002) FHIT: from gene discovery to cancer treatment and prevention. Lancet Oncol 3: 748-754
30. Roz L, Gramegna M, Ishii H, Croce CM, Sozzi G (2002) Restoration of fragile histidine triad (FHIT) expression includes apoptosis and suppresses tumorigenicity in lung and cervical cancer cell lines. Proc Natl Acad Sci USA 99: 3615-3620
31. Roz L, Andriani F, Ferreira CG, Giaccone G, Sozzi G (2004) The apoptotic pathway triggered by the Fhit protein in lung cancer cell lines is not affected by Bcl-2 or Bcl-x(L) overexpression. Oncogene 23: 9102-9110
32. Santos SCL, Cavalli LR, Cavalli IJ, Lima RS, Haddad BR, Ribeiro EMSF (2004) Loss of heterozygosity of the BRCA1 and FHIT genes in patients with sporadic breast cancer from Southern Brazil. J Clin Pathol 57: 374-377
33. Sauer T, Beraki K, Noren T, Garred O, Naess O (2005) EGFR gene copy number heterogeneity in fine-needle aspiration cytology from breast carcinomas determined by chromogenic in situ hybridization. Diagn Cytopathol 33: 228-232
34. Shi Y, Zou M, Farid NR, Paterson MC (2000) Association of FHIT (fragile histidine triad), a candidate tumour suppressor gene, with the ubiquitin-conjugating enzyme hUBC9. Biochem J 352: 443-448
35. Stark A, Hulka BS, Joens S, Novotny D, Thor AD, Wold LE, Schell MJ, Melton LJ, Liu EY, Conway K (2000) Her-2/neu amplification in benign breast disease and the risk of subsequent breast cancer. J Clin Oncol 18: 267-274
36. Steck K, El-Naggar AK (1994) Comparative flow cytometric analysis of Ki-67 and proliferating cell nuclear antigen (PCNA) in solid neoplasms. Cytometry 17: 258-265
37. Taylor J, Lymboura M, Pace PE, A'Hern RP, Desai AJ, Shousha S, Coombes RC, Ali S (1998) An important role for BRCA1 in breast cancer progression is indicated by its loss in a large proportion of non-familial breast cancers. Int J Cancer 79: 334-342
38. Terry G, Ho L, Londesborough P, Cross P, Lopes A, Monaghan J, Cuzick J (2004) The role of human papillomavirus type 16 and the fragile histidine triad gene in the outcome of cervical neoplastic lesions. Br J Cancer 91: 2056-2062
39. True L, Coleman I, Hawley S, Huang CY, Gifford D, Coleman R, Beer TM, Gelmann E, Datta M, Mostaghel E, Knudsen B, Lange P, Vessella R, Lin D, Hood L, Nelson PS (2006) A molecular correlate to the Gleason grading system for prostate adenocarcinoma. Proc Natl Acad Sci USA 103: 10991-10996
40. Turner BC, Ottey M, Zimonjic DB, Potoczek M, Hauck WW, Pequignot E, Keck-Waggoner CL, Sevignani C, Aldaz CM, McCue PA, Palazzo J, Huebner K, Popescu NC (2002) The fragile histidine triad/common chromosome fragile site 3B locus and repair-deficient cancers. Cancer Res 62: 4054-4060
41. Wilson CA, Ramos L, Villasenor MR, Anders KH, Press MF, Clarke K, Karlan B, Chen J-J, Scully R, Livingston D, Zuch RH, Kanter MH, Cohen S, Calzone FJ, Slamon DJ (1999) Localization of human BRCA1 and its loss in high grade, non-inherited breast carcinomas. Nat Gen 21: 236-240
42. Winter RN, Kramer A, Borkowski A, Kyprianou N (2001) Loss of caspase-1 and caspase-3 protein expression in human prostate cancer. Cancer Res 61: 1227-1232
43. Yang Q, Yoshimura G, Suzuma T, Tamaki T, Umemura T, Nakamura M, Nakamura Y, Wang X, Mori I, Sakurai T, Kakudo K (2001) Clinicopathological significance of fragile histidine triad transcription protein expression in breast carcinoma. Clin Cancer Res 7: 3869-3873